99 PEAK and PINNACLE – Key question: Why are the primary and key secondary endpoints evaluated up to Week 24 and not at Week 16? Optimizing the timing of the primary and key secondary endpoints from Week 16 to Week 24, maximizes the vision gains (mean change and categorical) 0 5 10 15 20 25 30 0 4 8 12 16 20 24 Evaluating the key secondary endpoints over time maximizes the chance of capturing the categorical change and thus, meeting the key secondary endpoint Patient treated with KSI-101 5 mg APEX Case Example Vision continues to improve over time Using a single timepoint (Week 16) to evaluate ≥15 letter gains reduces the chances of capturing the categorical change +15 +14 +25 +28 Change in BCVA at Week 16: +14 ≥15 letter gainer at Week 16: no Change in BCVA at Week 20 and 24: +26.5 ≥15 letter gainer up to Week 24: yes Preliminary results. As the APEX study is ongoing, final results may be different due to data cleaning. Change in BCVA, letters